Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENLON-PLUS vs BYFAVO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enlon-Plus (neostigmine methylsulfate and glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and an anticholinergic agent (glycopyrrolate). Neostigmine inhibits acetylcholinesterase, increasing acetylcholine concentration at cholinergic synapses, enhancing neuromuscular transmission. Glycopyrrolate counteracts muscarinic side effects (e.g., bradycardia, excessive secretions) without affecting nicotinic actions.
Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.
Reversal of non-depolarizing neuromuscular blocking agents after surgery,Off-label: Treatment of myasthenia gravis (neostigmine component)
Improvement of excessive daytime sleepiness in adult patients with obstructive sleep apnea (OSA) as an adjunct to upper airway stimulation therapy
1 to 2 m L (0.5 to 1 mg neostigmine methylsulfate with 0.2 to 0.4 mg glycopyrrolate) IV over 1 minute; may repeat in 10-15 minutes if needed; maximum total dose: 5 m L.
For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.
Terminal elimination half-life: 3.5–4.5 hours (prolonged in hepatic impairment).
Terminal elimination half-life is approximately 2-4 hours; clinical context: requires continuous infusion for sustained effect, as rapid clearance may lead to loss of efficacy.
Neostigmine: Hydrolyzed by cholinesterases and metabolized in the liver via microsomal enzymes. Glycopyrrolate: Not significantly metabolized; eliminated unchanged in urine and bile.
Primarily metabolized by CYP3A4 and CYP2D6, with minor contribution from CYP1A2.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites.
Renal excretion accounts for approximately 90% of the administered dose, with <5% as unchanged drug. Biliary/fecal elimination is minimal (<5%).
Plasma protein binding: 55–65%, primarily to albumin.
Approximately 70-80% bound to human serum albumin and alpha-1-acid glycoprotein.
Vd: 0.8–1.2 L/kg, indicating distribution into total body water.
Volume of distribution (Vd) is 0.3-0.5 L/kg; clinical meaning: indicates moderate distribution into tissues, not extensive peripheral sequestration.
Oral: 70–80% (first-pass effect); IM: 100%.
Bioavailability is not applicable for intravenous formulation; oral bioavailability is negligible due to extensive first-pass metabolism (<5% if administered orally).
Cr Cl 10-50 m L/min: Use 50% of dose. Cr Cl <10 m L/min: Use 25% of dose. Adjust based on neostigmine component due to renal excretion.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), consider reduced infusion rate due to prolonged recovery times; specific dose not established.
No specific adjustment required; neostigmine minimally hepatically metabolized.
Child-Pugh A and B: No adjustment. Child-Pugh C: Reduce infusion rate by 50% and monitor for prolonged sedation; starting infusion at 0.75 mg/kg/hour is recommended.
0.04 mg/kg neostigmine methylsulfate with 0.02 mg/kg glycopyrrolate IV; may repeat in 10-15 minutes if needed; maximum single dose: 2 m L.
Not approved for pediatric patients <18 years of age. Safety and efficacy not established.
Use with caution; consider lower initial doses due to potential renal impairment; monitor for bradycardia and excessive cholinergic effects.
For patients ≥65 years, consider lower initial infusion rate (1 mg/kg/hour) and reduce bolus doses; titrate carefully due to increased sensitivity and slower emergence from anesthesia.
Should be used only when facilities for immediate endotracheal intubation, artificial respiration, and oxygen therapy are available. Bradycardia and cardiac arrest have occurred. Administer in the presence of an anesthesiologist or other qualified clinician.
Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).
Risk of severe bradycardia, hypotension, and cardiac arrest. Use caution in patients with asthma, epilepsy, bradyarrhythmias, recent myocardial infarction, or hyperthyroidism. May increase bronchial secretions. Avoid in patients with mechanical obstruction of the gastrointestinal or urinary tract.
Risk of transient ischemic attacks and seizures; discontinue use if neurological symptoms occur.,May cause dose-related increases in blood pressure and heart rate; monitor cardiovascular status.,Not recommended in patients with unstable cardiovascular disease, recent myocardial infarction, or stroke.,Potential for drug interactions with strong CYP3A4 inhibitors or inducers.,May cause insomnia, anxiety, or restlessness.
Known hypersensitivity to neostigmine, glycopyrrolate, or any component. Contraindicated in patients with peritonitis, mechanical intestinal obstruction, or urinary tract obstruction.
Hypersensitivity to BYFAVO or any of its components,Severe hepatic impairment (Child-Pugh Class C)
No specific food interactions are reported. Maintain adequate hydration. Avoid excessive caffeine or alcohol, which may affect heart rate or fluid balance.
No specific food interactions are reported. However, because sedation may cause nausea, avoid heavy meals immediately before sedation. Grapefruit juice does not significantly interact with remimazolam.
First trimester: No adequate studies in pregnant women; animal studies not available. Risk cannot be ruled out. Second/third trimester: Potential fetal toxicity (respiratory depression, bradycardia) if used near term. Avoid use during labor due to risk of neonatal respiratory depression.
BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. Effective contraception required.
Not recommended. Unknown M/P ratio. Atropine and pralidoxime (components of ENLON-PLUS) may enter breast milk; potential for infant anticholinergic effects and gastrointestinal disturbances.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No established dose adjustments. Increased plasma volume and renal clearance in pregnancy may reduce drug concentrations; however, no pharmacokinetic studies available. Titrate to effect with caution.
No pharmacokinetic data in pregnancy; standard dosing is not recommended as drug is contraindicated. If use is unavoidable, no specific dose adjustment guidelines exist; use with extreme caution and consider alternative therapy.
ENLON-PLUS (neostigmine/glycopyrrolate) is used for reversal of non-depolarizing neuromuscular blockade. Neostigmine inhibits acetylcholinesterase, increasing ACh at the neuromuscular junction; glycopyrrolate is an anticholinergic to counteract muscarinic side effects (bradycardia, excessive secretions). Monitor heart rate closely; glycopyrrolate may cause tachycardia. Administer IV slowly over 1 minute. Onset is 5-10 minutes; peak effect at 10-20 minutes. Use with caution in patients with bradycardia, asthma, or peptic ulcer disease.
BYFAVO (remimazolam) is an ultra-short-acting benzodiazepine for procedural sedation. Onset within 1-2 minutes, recovery typically within 10 minutes. Flumazenil is the reversal agent. Monitor for respiratory depression; have resuscitation equipment available. Avoid in severe hepatic impairment. Coadministration with opioids increases sedation depth; reduce doses accordingly.
This medication is given to reverse muscle relaxants after surgery.,You may experience changes in heart rate; tell your doctor if you feel palpitations or chest discomfort.,Dry mouth and blurred vision are possible side effects due to the glycopyrrolate component.,Inform your healthcare provider if you have a history of heart problems, asthma, or stomach ulcers.,You may feel temporary muscle weakness or twitching as the medication works.
You will be closely monitored during the procedure. Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication.,Inform your healthcare provider if you have a history of liver disease, glaucoma, or substance abuse.,Do not consume alcohol for at least 24 hours after sedation.,You may experience temporary memory loss or drowsiness; arrange for a responsible adult to accompany you home.,Report any unusual side effects such as prolonged drowsiness, difficulty breathing, or allergic reactions (rash, swelling) to your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENLON-PLUS vs BYFAVO, answered by our medical review team.
ENLON-PLUS is a Cholinesterase Inhibitor Combination that works by Enlon-Plus (neostigmine methylsulfate and glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and an anticholinergic agent (glycopyrrolate). Neostigmine inhibits acetylcholinesterase, increasing acetylcholine concentration at cholinergic synapses, enhancing neuromuscular transmission. Glycopyrrolate counteracts muscarinic side effects (e.g., bradycardia, excessive secretions) without affecting nicotinic actions.. BYFAVO is a Benzodiazepine that works by Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENLON-PLUS and BYFAVO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENLON-PLUS is: 1 to 2 m L (0.5 to 1 mg neostigmine methylsulfate with 0.2 to 0.4 mg glycopyrrolate) IV over 1 minute; may repeat in 10-15 minutes if needed; maximum total dose: 5 m L.. The standard adult dose of BYFAVO is: For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENLON-PLUS and BYFAVO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENLON-PLUS is classified as Category C. First trimester: No adequate studies in pregnant women; animal studies not available. Risk cannot be ruled out. Second/third trimester: Potential fetal toxicity (respiratory depres. BYFAVO is classified as Category C. BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.